-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris net loss widens to $10.9 million in Q1 2026

PUBT·05/12/2026 12:04:39
Listen to the news
Kalaris net loss widens to $10.9 million in Q1 2026
  • Kalaris Therapeutics posted a Q1 net loss of USD 10.9 million, widening from USD 10.2 million a year earlier.
  • Research and development expense rose to USD 7.6 million from USD 6 million, while general and administrative expense held at USD 4.3 million.
  • Cash, cash equivalents and marketable securities fell to USD 104.9 million as of March 31, 2026 from USD 118 million at year-end 2025.
  • Patient screening began in Phase 1b/2 multiple ascending dose study of TH103 in neovascular age-related macular degeneration, with preliminary data expected in 1H 2027.
  • Planned Phase 3 trials remain on track for 2027 year-end initiation, with cash expected to fund operations into Q4 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120800PRIMZONEFULLFEED9717873) on May 12, 2026, and is solely responsible for the information contained therein.